Pricing Log in Create free account
Friday 6 November 2026 Export BLLN’s income statement to Excel — free account

BillionToOne, Inc.

BLLN Healthcare Diagnostics & Research

BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.

Revenue
+47.2%
EPS
+164.3%
Free cash flow
+9.25%
Total debt
+60.6%

Quarter to September 2026, against a year earlier

111.54 0.85 −0.76%
Market cap
$5.3B
P/E
88.7×
Fwd P/E
146×
Dividend yield
—
F-score
n/a
Altman Z
6.04
Beneish M
−2.03
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

BillionToOne, Inc. (BLLN) Debt to equity

Alert me on Debt to equity

BillionToOne, Inc.'s debt to equity at the end of the quarter to 30 September 2026 was 0.0×, down 0.1× from fiscal 2025 (0.1×). That is below the Diagnostics & Research industry median of 0.0× and in line with the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.1× —
FY2024 −0.2× —
FY2023 0.0× —

Quarterly newest first

Period Debt to equity Change
Sep 2026 0.0× —
Jun 2026 0.2× (4.82%)
Mar 2026 0.2× 48.87%
Dec 2025 0.1× —
6 more quarters

Debt to equity against peers

Company Debt to equity
VCYT Veracyte, Inc. compare 0.0×
CDNA CareDx, Inc. compare 0.0×
GRAL GRAIL, Inc. compare 0.0×
BLLN BillionToOne, Inc. 0.0×
ADPT Adaptive Biotechnologies Corporation compare 0.0×
NEO NeoGenomics, Inc. compare 0.5×
QGEN QIAGEN N.V. compare 0.5×
RDNT RadNet, Inc. compare 0.9×
SHC Sotera Health Company compare 3.1×
Diagnostics & Research industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on BLLN